3–Aminoazetidin–2–one Derivatives as *N*–Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration

Dr. Annalisa Fiasella[a],#, **Dr. Andrea Nuzzi**[a],#, **Dr. Maria Summa**[a], **Dr. Andrea Armirotti**[a], **Dr. Glauco Tarozzo**[a], **Prof. Giorgio Tarzia**[b], **Prof. Marco Mor**[c], **Dr. Fabio Bertozzi**[a], **Dr. Tiziano Bandiera***,[a], and **Prof. Daniele Piomelli***,[a],[d]

Tiziano Bandiera: tiziano.bandiera@iit.it; Daniele Piomelli: daniele.piomelli@iit.it

[a]Drug Discovery and Development, Istituto Italiano di Tecnologia, Via Morego 30, I–16163 Genova (Italy), Fax: +39–010–71781228

[b]Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino „Carlo Bo", Piazza del Rinascimento 6, I-61029 Urbino (Italy)

[c]Dipartimento di Farmacia, Università degli Studi di Parma, Viale della Scienze 27/A, I-43124 Parma (Italy)

[d]Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, 3216 Gillespie Neuroscience Facility Irvine, California 92697–4621 (United States)

Abstract

N Acylethanolamine acid amidase (NAAA) is a cysteine hydrolase that catalyzes the hydrolysis of endogenous lipid mediators such as palmitoylethanolamide (PEA). PEA has been shown to exert anti–inflammatory and antinociceptive effects in animals by engaging peroxisome proliferator–activated receptor–α (PPAR–α). Thus preventing PEA degradation by inhibiting NAAA may provide a novel approach for the treatment of pain and inflammatory states. Recently, 3–aminooxetan–2–one compounds were identified as a class of highly potent NAAA inhibitors. The utility of these compounds is limited, however, by their low chemical and plasma stabilities. In the present study, we synthesized and tested a series of *N*–(2–oxoazetidin–3–yl)amides as a novel class of NAAA inhibitors with good potency and improved physicochemical properties, suitable for systemic administration. Moreover, we elucidated the main structural features of 3–aminoazetidin–2–one derivatives that are critical for NAAA inhibition.

Keywords

β-lactams; NAAA; inhibitors; stability; structure-activity relationship

---

Introduction

Fatty acid ethanolamides (FAEs) are a family of lipid–derived messengers that play important roles in the control of pain, inflammation and energy balance.[1] Two structurally and functionally distinct classes of FAEs have been described: polyunsaturated FAEs, such as arachidonoylethanolamide (anandamide), which are endogenous ligands for cannabinoid receptors and participate, among other functions, in the control of stress–coping responses and pain initiation;[2] and monounsaturated and saturated FAEs, such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), which are endogenous ligands for peroxisome proliferator–activated receptor–α (PPAR–α) and are involved in energy balance, pain and inflammation.[1a]

Within the latter class, PEA, the endogenous amide of palmitic acid and ethanolamine, has been shown to inhibit peripheral inflammation and mast cell degranulation[3] and to exhibit antinociceptive properties in rat and mouse models of acute and chronic pain.[3b, 4] Those properties depend on PPAR–α activation because they are absent in PPAR–α-null mice, are mimicked by synthetic PPAR–α agonists and are blocked by PPAR–α antagonists.[5] Furthermore, PEA has been reported to suppress pain behaviors induced by tissue injury, nerve damage or inflammation in mice[5c] and to attenuate skin inflammation and neuropathic pain in humans.[6]

Tissue FAE levels are regulated at the level of biosynthesis and degradation.[7] A molecularly unique phospholipase D releases FAEs from precursor N–acylphosphatidylethanolamines (NAPEs) present in cell membrane.[8] FAEs degradation to the corresponding free fatty acids and ethanolamine is carried out by either fatty acid amide hydrolase (FAAH) or N–acylethanolamine acid amidase (NAAA).[9] These two intracellular lipid amidases show different cellular localization and substrate selectivity with NAAA preferentially catalyzing the hydrolysis of PEA and OEA in innate immune cells.[4b]

NAAA[10] is a cysteine amidase that belongs to the N–terminal nucleophile (Ntn) family of enzymes,[11] and is characterized by a conserved amino acid catalytic triad Cys, Arg and Asp. The primary structure of NAAA has no homology with that of FAAH,[11] while it shares 33–34% identity and 70% similarity to acid ceramidase (AC), a cysteine amidase involved in the hydrolysis of the sphingolipid messenger ceramide. NAAA is thought to be localized to lysosomes[12] and shows common features with other lysosomal hydrolases, i.e. N–glycosylation, autoproteolytic cleavage[13] and activation at acidic pH (around 4.5–5.0).[9a] After its maturation, the N–terminal cysteine residue (Cys–131 in rodents; Cys–126 in humans) is responsible for the catalytic cleavage of nonpeptide C–N bonds in linear amides;[14] for this reason, NAAA is also linked to the choloylglycine hydrolase superfamily.[11] Site–directed mutagenesis[15] and mass spectrometry studies[16] have unambiguously identified human Cys–126 as the nucleophile responsible for both autoproteolysis and activity.

Recently, inhibition of NAAA activity has attracted increasing interest as a strategy to sustain endogenous PEA and OEA levels, and the enzyme has been envisaged as a new potential therapeutic target for inflammation.[5a]

So far, only a limited number of natural[17] or synthetic[18] NAAA inhibitors have been reported in the literature. Among them, α–amino–β–lactone (3–aminooxetan–2–one) derivatives have shown considerable promise because of their high inhibitory potency and target selectivity.[19] In particular, in vitro and in vivo studies have demonstrated that (S)–N–(2–oxo–3–oxetanyl)–3–phenylpropionamide ((S)–OOPP, **1**, Figure 1), which inhibits rat-NAAA (r-NAAA) with a median inhibitory concentration (IC$_{50}$) of 0.42 μM [19a, 19f], blocks FAE hydrolysis in activated inflammatory cells and dampens tissue reactions to various pro–inflammatory stimuli.[19b] More recently, 5–phenylpentyl N–[(2S,3R)–2–methyl–4–oxo–oxetan–3–yl]carbamate (ARN077, **2**, Figure 1, r-NAAA IC$_{50}$ = 0.050 μM),[19c, 19d, 19f] a new potent and selective β–lactone NAAA inhibitor, was shown to elevate PEA and OEA levels in mouse skin and sciatic nerve tissues, and to attenuate nociception in mice and rats following topical administration.[20]

Despite their high potency and efficacy, β–lactone–based NAAA inhibitors suffer from limited chemical and plasma stabilities[19c, 19e] due to the facile ring–opening to the corresponding β–hydroxyacid. Their low chemical stability makes these derivatives suitable for topical applications,[19c, 19e] but prevents their use as systemic agents.

To further explore the therapeutic utility of NAAA inhibitors, we started a program aimed at identifying new chemical series that might be suitable for systemic administration. Within this program, we investigated functionalized α–amino-β–lactam (3–amidoazetidin–2–one) derivatives, a chemo–type structurally similar to the 3–aminooxetan–2–one, to test whether the replacement of the β–lactone core with a β–lactam retained inhibitory activity towards NAAA, while increasing chemical and plasma stabilities.

In the present work, we report the discovery of 3–aminoazetidin–2–ones as a new class of NAAA inhibitors endowed with good potency and promising chemical and plasma stabilities, which may make these derivatives suitable for systemic administration. In particular, we prepared a small series of β–lactam analogues and evaluated their inhibitory activity on human NAAA (h–NAAA). This study allowed us to highlight key structural features for NAAA inhibition and derive an initial structure–activity relationship (SAR).

Chemistry

Differently substituted 3–aminoazetidin–2–one derivatives were efficiently accessed in an enantioselective fashion, starting from the corresponding D– or L–N–protected–serine derivatives.

As reported in Scheme 1, the designed synthetic route envisaged both the (S)– and (R)–2–oxoazetidin–3–yl–ammonium acetate (**9** and **10**),[21] as key intermediates for the synthesis of 3–aminoazetidin–2–one amide derivatives bearing different side chains. Notably, by modifications and optimization of literature procedures,[22] compounds **9** and **10** were prepared in multigram scale, with 40–44% overall yield over four steps.[23]

First, benzyloxycarbonyl (Cbz)–protected azetidinones **7** and **8** were prepared following a three–step sequence.[22a] Amide coupling between p–anisidine and N–[(benzyloxycarbonyl)]–L– and D–serine, afforded intermediates **3** and **4**, which were

converted into the corresponding *N*–protected α–amino–β–lactams **5** and **6** by a one–pot cyclization reaction, which represents the key step in this synthesis. Subsequent *p*–methoxyphenyl deprotection with ceric ammonium nitrate in a 1:1 mixture of MeCN/H$_2$O led to β–lactams **7** and **8**. Then, Cbz-deprotection[22b] was carried out by catalytic transfer hydrogenation, using 1,4–cyclohexadiene as hydrogen source in the presence of 10% palladium on charcoal.[24] The resulting unprotected 3–aminoazetidin–2–ones were immediately trapped as acetate salts **9** and **10**, which could be easily stored for several months.

Coupling reactions of salt **9** with the suitable acyl chloride in the presence of triethylamine afforded amides **11a**, **11f**–**h** and **11l** and **11o**, while reaction of enantiomer **10** with nonanoyl chloride led to compound **12h** (Method A, Scheme 1).

Alternatively, the reaction of compound **9** with the appropriate carboxylic acid, activated with TBTU and triethylamine, gave amides **11b**–**e**, **11i**–**k**, **11m**–**n** and **11p**–**q** (Method B, Scheme 1). In all coupling reactions no racemization at the stereogenic α–center was detected.

All the employed acyl chlorides and most of the carboxylic acids were commercially available; carboxylic acids **13**, **14** and **15** were prepared as reported in Scheme 2.

Compound **13** was synthesized by saponification of commercially available methyl (*E*)–3–nonenoate (Scheme 2).

The preparation of (*Z*)–non–3–enoic acid (**14**) was accomplished in two steps starting from commercially available (*Z*)–non–3–en–1–ol. Oxidation with Dess–Martin periodinane[25] led to the exclusive formation of (*Z*)–non–3–enal (**16**) (Scheme 2). Further oxidation under Pinnick reaction conditions, in the presence of 2–methy–2–butene as scavenger, selectively yielded acid **14** as a single diastereoisomer.

Carboxylic acid **15** was prepared starting from 5–cyclohexylpentan–1–ol (**17**)[26] which was first oxidized to aldehyde **18**. Subsequent Horner–Emmons olefination afforded the α,β–unsaturated ester **19**, which was subjected to hydrogenation followed by hydrolysis to furnish compound **15** (Scheme 2).

Compounds **21h**–**24h** were synthesized as reported in Scheme 3.

Cyclobutanone derivative **21h** was prepared by the acid–catalyzed reaction of 1,2–bis(trimethylsilanoxy)cyclobutene with amide **25**, obtained by alkaline hydrolysis of nonanenitrile (Scheme 3).[19c] The synthesis of compound **22h** was accomplished starting from commercially available *N*–Boc–3–amino–azetidine by standard amide coupling with nonanoyl chloride followed by Boc deprotection with TFA/DCM (Scheme 3). Acid–mediated ring opening of **11h** smoothly delivered compound **23h** as hydrochloride salt in good yield (Scheme 3). Finally, standard amide coupling of nonanoyl chloride with commercially available (3*S*)–3–aminopyrrolidin–2–one led to derivative **24h** (Scheme 3).

Then, *N*–methylated amides **27h** and **28h** were prepared as reported in Scheme 4.

Alkylation of azetidinone **11h** with methyl iodide in the presence of sodium hydride in DMF selectively occurred on the *N*1–endocyclic nitrogen, providing compound **27h** (Scheme 4).

Alkylation of the protected β–lactam **5** with methyl iodide, under standard conditions, afforded compound **29** in good yield. Cleavage of the *p*–anisyl group followed by catalytic hydrogenation led to the *N*–methyl acetate salt **31**, which gave *N*–methyl derivative **28h** after amide coupling with nonanoyl chloride, using Method A (Scheme 4).

The acetate salt **9** was used to access amine, urea and carbamate derivatives **32**, **33** and **34**, respectively, as reported in Scheme 5.

Amine derivative **32** was synthesized by reductive amination of aldehyde **35**, obtained by oxidation of *n*–nonanol, with salt **9**, while urea **33** was obtained treating **9** with nonyl isocyanate in the presence of catalytic DMAP (Scheme 5).

Carbamate **34** was synthesized in a two-step sequence. *n*–Heptanol was reacted with 2–pyridyl carbonate (2–DPC)[19d, 27] and catalytic DMAP to give an isomeric mixture of 2–pyridyl carbonate **36** and 2–oxopyridine–1–carboxylate **37** (65:35 ratio), which was then coupled with **9** affording the desired compound **34** in good yield (Scheme 5).

Structure–Activity Relationship (SAR) and Stability Studies

The aim of the present study was to explore substituted 3–aminoazetidin–2–one derivatives as a novel class of NAAA inhibitors potentially suitable for systemic administration. The new compounds were tested for their ability to inhibit the hydrolysis of *N*–(4–methyl–2–oxo–chromen–7–yl)–hexadecanamide (PAMCA) by recombinant *h*–NAAA heterologously expressed in HEK293 cells (see Experimental Section).[16] Median inhibitory concentration (IC_{50}) values are reported in Tables 1, 3 and 4. A few representative compounds were also evaluated for their chemical stability in buffer at pH 7.4 and 5.0[28] and for their stability in mouse plasma (Table 2).

We utilized the β–lactam derivative **11a** (Table 1), an analogue of the known β-lactone NAAA inhibitor (*S*)–OOPP (**1**, Figure 1) ([19a] *h*–NAAA IC_{50}: 1.29 μM), as starting point for our initial SAR work. Disappointingly, **11a** turned out to be inactive. However, the compound showed substantially higher hydrolytic stability ($t_{1/2}$ > 1440 min at both pH 7.4 and pH 5.0) and promising mouse–plasma stability ($t_{1/2}$ > 120 min) and rat-plasma stability ($t_{1/2}$ > 120 min) compared to its β–lactone analogue (*S*)-OOPP ($t_{1/2}$ < 1 min) (Table 2).

Based on previous SAR results with the β–lactone class,[19d] we hypothesized that activity might be recovered by increasing the length of the amide side-chain. Therefore, a small set of analogues was prepared where the length of the phenylalkyl chain of **11a** was progressively increased from 2 to 6 methylene units (**11b–e**, Table 1). Confirming our hypothesis, NAAA inhibitory activity, albeit in the high micromolar range, was observed for compounds **11b** (IC_{50} = 73.36 μM) and **11c** (IC_{50} = 27.16 μM), while the 6–phenylhexyl analogue **11e** showed submicromolar potency (IC_{50} = 0.60 μM). Removal of the phenyl group from **11e** led to compound **11f** (IC_{50} = 27.02 μM), which showed a >40–fold drop in potency compared to **11e**. A good inhibitory activity against NAAA was again recovered by

increasing the length of the alkyl chain from six to eight carbon atoms as in analogue **11h** ($IC_{50} = 0.34$ μM), which turned out to be the most potent derivative within this small series of compounds. Notably, the β–lactam **11h** retained a favorable chemical and plasma stability profile (Table 2), proving to be stable to chemical hydrolysis over 24 h ($t_{1/2} > 1440$ min), and showing acceptable half–life in mouse and rat plasma ($t_{1/2} = 103$ min and > 120 min, respectively).

These initial results suggested that *N*–(2–oxoazetidin–3–yl)amide derivatives may hold potential as a new potent and stable class of NAAA inhibitors.

Encouraged by these results, we considered compound **11h** as the prototype for this novel class of inhibitors, and synthesized a first set of analogues to identify the key structural features for NAAA inhibition.

We first modified the 3–aminoazetidin–2–one scaffold, while maintaining fixed the amide chain: the stereochemistry at the C(3) position was inverted, the nitrogen and the carbonyl group of the azetidinone ring were replaced by a methylene, the β–lactam ring was hydrolyzed and expanded to the five atoms homologue (γ–lactam). Finally, the endocyclic nitrogen was methylated to assess the stereoelectronic requirements at this position.

The importance of the (*S*)–configuration for the substituent at C(3) position was clearly demonstrated by the >200–fold loss in potency observed with compound **12h** ($IC_{50} = 74.52$ μM, Table 3), the (*R*)–enantiomer of **11h**. This stereochemical preference is in agreement with previous observations on serine–derived β–lactone inhibitors.[19a, 19b] Replacement of the endocyclic nitrogen with a methylene (**21h**), reduction of the azetidinone to an azetidine ring (**22h**), ring–opening of the azetidinone (**23h**), and ring–expansion to γ–lactam (**24h**) all led to loss of activity, as previously observed in the β–lactone series.[19a, 19b] Methylation of the *N*1–endocyclic nitrogen (**27h**), abolished the NAAA inhibitory activity. These findings unambiguously indicated that an intact β–lactam moiety was mandatory for NAAA inhibition.

We then focused our attention on the amide function at the C(3) position of the azetidinone ring. The exocyclic nitrogen was methylated, leading to compound **28h**, and the amide was replaced by a *n*–nonylamino group, as in compound **32**. Both derivatives turned out to be inactive. A secondary amide at C(3) position of the azetidinone ring appears therefore to be required for NAAA inhibition.

As the next step in our SAR study, we directed our attention to the amide side chain, and explored the importance of the conformational flexibility, the substitution and the length of the alkyl chain.

First, we introduced a steric constraint in compounds **11i–j** (Table 4), two analogues of **11h** that contain a double bond in the *(E)* and *(Z)* configuration, respectively. Both changes resulted in a 10–fold drop in potency, with no preference for the alkene configuration (**11i**, $IC_{50} = 3.09$ μM; **11j**, $IC_{50} = 3.90$ μM). Further reduction of the side-chain flexibility by introduction of a para-substituted phenyl ring, as in compounds **11k–l**, led to a decrease (**11k**, $IC_{50} = 13.85$ μM) or loss (**11l**) of inhibitory activity. These findings indicated that the

insertion of sterically constrained amide chains is detrimental for activity, contrary to what observed with β–lactone amides.[19c]

We also synthesized compounds bearing a branched aliphatic side-chain (**11m** and **11n**). A single methyl group close to the amide function appeared to be well accommodated as compound **11m** (IC_{50} = 0.22 μM), although as a mixture of diastereoisomers, showed a slight increase in potency compared to compound **11h**. However, the introduction of a *gem*-dimethyl group in the same position, as in derivative **11n** (IC_{50} = 0.76 μM), was detrimental for potency.

We then turned our attention to analogues with longer alkyl chains, and prepared compounds containing a decanamide (**11o**) and undecanamide residue (**11p**). The compounds showed improved NAAA inhibitory activity (**11o**, IC_{50} = 0.24 μM; **11p**, IC_{50} = 0.10 μM). This result supports the idea that linear lipophilic moieties, which resemble the natural enzyme substrate, are well accommodated in the active site.

The insertion of a terminal cyclohexyl moiety, as in amide **11q** (IC_{50} = 0.28 μM), resulted in a slight decrease in potency compared to **11p** (Table 4), but a two–fold potency increase with respect to phenyl analogue **11e** (Table 1).

Finally, we investigated the impact of the functionality at the *N*3–exocyclic amino group of the β–lactam on NAAA inhibition by synthetizing the corresponding urea (**33**) and carbamate (**34**) analogues of amide **11h** (Table 4).

The replacement of the amide moiety with a urea, as in derivative **33** (IC_{50} = 5.76 μM), resulted in a marked decrease in potency. By contrast, the carbamate **34** (IC_{50} = 0.24 μM) was interestingly more potent than the amide **11h**.

NAAA shows 33–34% identity and 70% similarity to AC, a cysteine amidase that catalyzes the deactivating hydrolysis of the pro-inflammatory lipid messenger, ceramide. We tested therefore the most representative compounds identified in our study (**11h**, its enantiomer **12h**, and **11p**) for their selectivity against human AC and FAAH. The selectivity of compounds **11h**, **12h** and **11p** versus AC was evaluated using an UPLC–MS–based assay[19a, 29] in order to measure IC_{50} values under similar experimental conditions. The results are reported in Table 5.

Compound **11h** showed ca. 19–fold selectivity for NAAA vs. AC (*h*–NAAA IC_{50} = 0.13 μM; *h*–AC IC_{50} = 2.53 μM) while its enantiomer, **12h**, displayed low potency on the two enzymes (*h*–NAAA IC_{50} = 45.5 μM; *h*–AC IC_{50} = 27.8 μM). Interestingly, lengthening the amide alkyl chain, as in compound **11p**, led to a ca. 7–fold increase in potency toward *h*–AC (IC_{50} = 0.33 μM) and a ca. 2–fold increase in potency toward *h*–NAAA (IC_{50} = 0.056 μM). Lengthening of the alkyl chain appeared therefore to have a more pronounced effect on AC than on NAAA, as indicated by the drop in selectivity vs. AC of analogue **11p** with respect to **11h**. None of the three selected compounds showed inhibitory activity toward *h*–FAAH.

The higher selectivity vs. AC of **11h** with respect to **11p**, coupled with its greater chemical and plasma stability, make this compound a potential probe for further exploration of the

functional role of NAAA. To test whether **11h** could be administered systemically, we dosed the compound intravenously (3.0 mg kg^{-1}) and orally (10 mg kg^{-1}) in rats, and determined its pharmacokinetic (PK) profile. Relevant PK parameters are reported in Table 6. Although **11h** showed a relatively high clearance (Cl = 702 mL min^{-1} kg^{-1}) by intravenous route, the oral PK profile was characterized by a maximal plasma concentration (C_{max}) of 570 ng mL^{-1} at 15 min postdosing, and a bioavailability of 67% (Table 6). These results support the use of **11h** as a NAAA inhibitor for systemic administration.

Conclusions

In the present work, we report the discovery of 3–aminoazetidin–2–one derivatives as a novel class of NAAA inhibitors. A series of *N*–(2–oxoazetidin–3–yl)amides were synthesized and tested to identify key structural features for NAAA inhibition. Our results showed that the β–lactam moiety is mandatory for activity, and that alkylation of the endocyclic nitrogen is not tolerated. The (*S*)–configuration of the acylamino substituent at C(3) position is strongly preferred over the (*R*)–configuration. The potency of *N*–(2–oxoazetidin–3–yl)amides as NAAA inhibitors is modulated by the amide alkyl chain, with long and flexible alkyl residues being preferred over sterically constrained chains. Interestingly, we found out that the amino group on the 3–aminoazetidin–2–one scaffold could be further derivatized as a carbamate (**34**) with retention of NAAA inhibitory activity (Figure 2). Further studies on this new series of derivatives are currently ongoing.

Among the synthesized compounds, *N*–[(*S*)–2–oxoazetidin–3–yl]nonanamide (**11h**) showed good inhibitory potency (IC$_{50}$ = 0.34 μM) against NAAA, ca. 19-fold selectivity versus AC - a closely related cysteine amidase - excellent chemical stability in buffer, and acceptable plasma stability. Importantly, this compound showed good oral bioavailability in rats.

Compound **11h** and other potent *N*–(2–oxoazetidin–3–yl)amide analogues represent promising probes that may help further characterize the functional roles of NAAA and assess the therapeutic potential of systemically available NAAA inhibitors.

Experimental Section

Chemistry

Chemicals, Materials and Methods—All the commercially available reagents and solvents were used as purchased from vendors without further purification. Dry solvents (DCM, THF, DMF, Pyridine, dichloroetane) were purchased from Sigma–Aldrich. Optical rotations were measured on a Rudolf Research Analytical Autopol II automatic polarimeter using a sodium lamp (589 nm) as the light source; concentrations are expressed in g/100 mL using MeOH as a solvent and a 1 dm cell. Automated column chromatography purifications were done using a Teledyne ISCO apparatus (Combi*Flash* R$_f$) with pre–packed silica gel columns (4 g). Mixtures of increasing polarity of cyclohexane (Cy) and ethyl acetate (EtOAc) were used as eluents. Column chromatography was performed manually on pre–packed silica cartridges (2 g or 5 g) from Biotage or on glass columns using Merck silica gel 60 (230–400 mesh) as stationary phase. Purifications by preparative HPLC–MS were run on a Waters Autopurification system consisting of a 3100 Single Quadrupole Mass

Spectrometer equipped with an Electrospray Ionization interface and a 2998 Photodiode Array Detector. HPLC system included a 2747 Sample Manager, 2545 Binary Gradient Module, System Fluidic Organizer and 515 HPLC Pump. The PDA range was 210–400 nm. Purifications were performed on a XBridgeTM Prep C18 OBD (100×19 mm i.d., particle size 5 μm) with a XBridgeTM Prep C18 (10×19 mm i.d., particle size 5 μm) Guard Cartridge. Mobile phase was 10 mM NH_4OAc in $MeCN–H_2O$ (95:5) at pH 5. Electrospray ionization in positive and negative mode was used. Hydrogenation reactions were performed using H–Cube® continuous hydrogenation equipment (SS–reaction line version), employing disposable catalyst cartridges (CatCart®) preloaded with the required heterogeneous catalyst. NMR experiments were run on a Bruker Avance III 400 system (400.13 MHz for ^1H, and 100.62 MHz for ^{13}C), equipped with a BBI probe and Z–gradients. Spectra were acquired at 300 K, using deuterated dimethylsulfoxide ([D_6]DMSO) or deuterated chloroform ($CDCl_3$) as solvents. UPLC–MS analyses were run on a Waters ACQUITY UPLC-MS system consisting of a SQD (Single Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface and a Photodiode Array Detector. PDA range was 210–400 nm. Analyses were performed on an ACQUITY UPLC HSS T3 C18 column (50×2.1mm i.d., particle size 1.8μm) with a VanGuard HSS T3 C18 pre–column (5×2.1 mm i.d., particle size 1.8μm). Mobile phase was either 10 mM NH_4OAc in H_2O at pH 5 adjusted with AcOH (A) and 10 mM NH_4OAc in $MeCN–H_2O$ (95:5) at pH 5 (B). Electrospray ionization in positive and negative mode was applied. Accurate mass measurement (HMRS) was performed on a Synapt G2 Quadrupole-Tof Instrument (Waters, USA), equipped with an ESI ion source.

All final compounds, **11a–q**, **12h**, **21h–24h**, **27h–28h**, **32–34** showed 95% purity by NMR and UPLC–MS analysis. The synthesis of reaction intermediates **9**, **10**, **13–15**, **25**, **26h**, **31**, **35–37** is described in the Supporting Information.

General procedures for the synthesis of amide derivatives 11a, 11f–h, 11l, 11o and 12h via Method A (Scheme 1)

Under nitrogen atmosphere, to a cooled (0 °C), stirred suspension of (2–oxoazetidin–3–yl)–ammonium acetate (**9** or **10**, 1.0 equiv) in dry DCM (0.07 M solution), or in a 3:1 mixture of dry DCM/DMF (0.07 M solution), dry Et_3N (2.1 equiv) and the suitable acid chloride (1.1 equiv) were added. The resulting mixture was stirred at r.t. for 16 h, then diluted with DCM and washed with sat. NH_4Cl solution, sat. $NaHCO_3$ solution and brine. The organic phase was dried over Na_2SO_4, filtered, concentrated to dryness and purified according to the specific conditions described in each example.

3–Phenyl–N–[(S)–2-oxoazetidin–3–yl]–propanamide (11a)—The reaction was carried out following Method A, using salt **9** (0.050 g, 0.34 mmol), commercially available hydrocinnamoyl chloride (0.056 mL, 0.38 mmol) and dry Et_3N (0.10 mL, 0.71 mmol) in dry DCM (5.0 mL). After work–up, trituration with EtOAc afforded compound **11a** (0.080 g, 15%), as a white solid: R_t = 1.40 min; $[\alpha]_D^{25}$=−10.8(c = 0.09 in MeOH); ^1H NMR (400 MHz, [D_6]DMSO): δ 8.51 (d, 1H, J = 8.2 Hz), 7.96 (bs, 1H), 7.29–7.24 (m, 2H), 7.22–7.14 (m, 3H), 4.87–4.80 (m, 1H), 3.38 (t, 1H, J = 5.4 Hz), 2.99 (dd, 1H, J = 5.4, 2.6 Hz), 2.81 (t, 2H, J = 7.9 Hz), 2.41 (t, 2H, J = 7.9 Hz) ppm; ^{13}C NMR (100 MHz, [D_6]DMSO): δ = 171.4,

168.0, 141.1, 128.3, 128.2, 125.4, 56.9, 42.9, 36.8, 30.9 ppm; MS (ESI, *pos*) *m/z*: 219 [M +H]$^+$, 241 [M+Na]$^+$, 257 [M+K]$^+$; MS (ESI, *neg*) *m/z*: 217 [M–H]$^-$; HRMS–ESI: *m/z* [M +H]$^+$ calcd for $C_{12}H_{15}N_2O_2$: 219.1134, found: 219.1136.

N–[(S)–2–Oxoazetidin–3–yl]–heptanamide (11f)—The reaction was carried out following Method A, using salt **9** (0.050 g, 0.34 mmol), commercially available heptanoyl chloride (0.058 mL, 0.38 mmol) and dry Et$_3$N (0.1 mL, 0.71 mmol) in dry DCM (5.0 mL). After work–up, purification by typical silica gel flash chromatography (DCM/MeOH, from 100:0 to 96:4) afforded compound **11f** (0.023 g, 34%), as a white solid: R_t = 1.63 min;

$[\alpha]_D^{25}$=−20.3 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.43 (d, 1H, *J* = 8.3 Hz), 7.94 (bs, 1H), 4.82 (ddd, 1H, *J* = 8.3, 5.4, 2.7 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.02 (dd, 1H, *J* = 5.4, 2.7 Hz), 2.08 (t, 2H, *J* = 7.4 Hz), 1.53–1.42 (m, 2H), 1.32–1.17 (m, 6H), 0.85 (t, 3H, *J* = 7.0 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.7, 168.7, 57.3, 43.3, 35.6, 31.5, 28.7, 25.5, 22.4, 14.4 ppm; MS (ESI, *pos*) *m/z*: 199 [M+H]$^+$, 221 [M+Na]$^+$, 237 [M +K]$^+$; MS (ESI, *neg*) *m/z*: 197 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{10}H_{19}N_2O_2$: 199.1447, found: 199.1449.

N–[(S)–2–Oxoazetidin–3–yl]–octanamide (11g)—The reaction was carried out following Method A, using salt **9** (0.060 g, 0.41 mmol), commercially available octanoyl chloride (0.076 mL, 0.45 mmol) and dry Et$_3$N (0.11 mL, 0.86 mmol) in dry DCM (6.0 mL). After work–up, trituration with EtOAc afforded compound **11g** (0.019 g, 22%), as a white solid: R_t = 1.88 min; $[\alpha]_D^{25}$=−10.5 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.43 (d, 1H, *J* = 8.2 Hz), 7.94 (bs, 1H), 4.82 (ddd, 1H, *J* = 8.2, 5.4, 2.4 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.02 (dd, 1H, *J* = 5.4, 2.4 Hz), 2.08 (t, 2H, *J* = 7.4 Hz), 1.53–1.42 (m, 2H), 1.32–1.17 (m, 8H), 0.85 (t, 3H, *J* = 7.0 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.2, 168.2, 56.8, 42.8, 35.1, 31.1, 28.5, 28.4, 25.1, 22.0, 13.9 ppm; MS (ESI, *pos*) *m/z*: 213 [M +H]$^+$, 251 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{11}H_{21}N_2O_2$: 213.1603, found: 213.1611.

N–[(S)–2–Oxoazetidin–3–yl]–nonanamide (11h)—The reaction was carried out following Method A, using salt **9** (0.60 g, 4.1 mmol), commercially available nonanoyl chloride (0.85 mL, 4.51 mmol) and dry Et$_3$N (1.2 mL, 8.6 mmol) in dry DCM (60 mL). After work–up, trituration with EtOAc afforded compound **11h** (0.60 g, 65%), as a white solid: R_t = 2.13 min; $[\alpha]_D^{25}$=−18.6 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.42 (d, 1H, *J* = 8.3 Hz), 7.94 (bs, 1H), 4.83 (ddd, 1H, *J* = 8.3, 5.3, 2.7 Hz), 3.38 (t, 1H, *J* = 5.3 Hz), 3.02 (dd, 1H, *J* = 5.3, 2.7 Hz), 2.08 (t, 2H, *J* = 7.3 Hz), 1.53–1.42 (m, 2H), 1.31–1.18 (m, 10H), 0.86 (t, 3H, *J* = 6.8 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.2, 168.2, 56.8, 42.8, 35.1, 31.2, 28.7, 28.6, 28.5, 25.1, 22.1, 13.9 ppm; MS (ESI, *pos*) *m/z:* 227 [M+H]$^+$, 249 [M+Na]$^+$, 265 [M+K]$^+$; MS (ESI, *neg*) *m/z:* 225 [M–H]$^-$; HRMS-ESI: *m/z* [M +H]$^+$ calcd for $C_{12}H_{23}N_2O_2$: 227.1760, found: 227.1771.

N–[(S)–2–Oxoazetidin–3–yl]–4–phenyl–benzamide (11l)—The reaction was carried out following Method A, using salt **9** (0.13 g, 0.89 mmol), commercially available 4–phenylbenzoyl chloride (0.21 g, 0.98 mmol) and dry Et$_3$N (0.26 mL, 1.87 mmol) in dry

DCM/DMF (4.0 mL). After work–up, trituration with EtOAc afforded compound **11l** (0.10 g, 42%), as a white solid: R_t = 1.89 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 9.14 (d, 1H, *J* = 8.5 Hz), 8.05 (bs, 1H), 7.97 (d, 2H, *J* = 8.4 Hz), 7.79 (d, 2H, *J* = 8.4 Hz), 7.74 (d, 2H, *J* = 7.4 Hz), 7.50 (t, 2H, *J* = 7.6 Hz), 7.45–7.38 (m, 1H), 5.09 (ddd, 1H, *J* = 8.5, 5.2, 2.5 Hz), 3.49 (t, 1H, *J* = 5.2 Hz), 3.27 (dd, 1H, *J* = 5.2, 2.5 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ 168.6, 166.1, 143.5, 139.5, 132.8, 129.4, 128.5, 127.3, 126.9, 58.5, 43.3; MS (ESI, *pos*) *m/z:* 267 [M+H]$^+$, 289 [M+Na]$^+$; MS (ESI, *neg*) *m/z:* 265 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{16}H_{15}N_2O_2$: 267.1134, found: 267.1133.

N–[(*S*)–2–Oxoazetidin–3–yl]–decanamide (11o)—

The reaction was carried out following Method A, using salt **9** (0.050 g, 0.34 mmol), commercially available decanoyl chloride (0.077 mL, 0.38 mmol) and dry Et$_3$N (0.11 mL, 0.71 mmol) in dry DCM (6.0 mL). After work–up, purification by typical silica gel flash chromatography (DCM/MeOH, from 100:0 to 96:4) afforded compound **11o** (0.051 g, 63%), as a white solid: R_t = 2.31 min; $[\alpha]_D^{25}$=−16.2 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.43 (d, 1H, *J* = 8.4 Hz), 7.94 (s, 1H), 4.82 (ddd, 1H, *J* = 8.4, 5.4, 2.7 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.02 (dd, 1H, *J* = 5.4, 2.7 Hz), 2.08 (t, 2H, *J* = 7.5 Hz), 1.53–1.42 (m, 2H), 1.33–1.16 (m, 12H), 0.86 (t, 3H, *J* = 7.1 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.7, 168.7, 57.3, 43.3, 35.6, 31.7, 29.3, 29.2, 29.1, 29.0, 25.5, 22.6, 14.4 ppm; MS (ESI, *pos*) *m/z:* 241 [M+H]$^+$, 263 [M+Na]$^+$, 279 [M+K]$^+$; MS (ESI, *neg*) *m/z:* 239 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{13}H_{25}N_2O_2$: 241.1916, found: 241.1920.

N–[(*R*)–2–Oxoazetidin–3–yl]–nonanamide (12h)—

The reaction was carried out following Method A, using salt **10** (0.090 g, 0.62 mmol), commercially available nonanoyl chloride (0.13 mL, 0.68 mmol) and dry Et$_3$N (0.18 mL, 1.03 mmol) in dry DCM (9.0 mL). After work–up, trituration with EtOAc afforded compound **12h** (0.074 g, 53%), as a white solid: R_t = 2.13 min; $[\alpha]_D^{25}$=+14.3 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.42 (d, 1H, *J* = 8.3 Hz), 7.94 (bs, 1H), 4.83 (ddd, 1H, *J* = 8.3, 5.3, 2.7 Hz), 3.38 (t, 1H, *J* = 5.3 Hz), 3.02 (dd, 1H, *J* = 5.3, 2.7 Hz), 2.08 (t, 2H, *J* = 7.3 Hz), 1.53–1.42 (m, 2H), 1.31–1.18 (m, 10H), 0.86 (t, 3H, *J* = 6.8 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.2, 168.2, 56.8, 42.8, 35.1, 31.2, 28.7, 28.6, 28.5, 25.1, 22.1, 13.9 ppm; MS (ESI, *pos*) *m/z:* 227 [M+H]$^+$, 249 [M+Na]$^+$, 265 [M+K]$^+$; MS (ESI, *neg*) *m/z:* 225 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{12}H_{23}N_2O_2$: 227.1760, found: 227.1766.

General procedures for the synthesis of amide derivatives 11b–e, 11i–k, 11m–n and 11p–q via Method B (Scheme 1)

Under nitrogen atmosphere, to a cooled (0 °C) solution of the suitable carboxylic acid (1.1 equiv) in dry DCM (0.07 M solution) or in a 3:1 mixture of dry DCM/DMF (0.07 M solution), dry Et$_3$N (2.2 equiv) was added followed by addition of *N,N,N′,N′*–tetramethyl–*O*–(benzotriazol–1–yl)uronium tetrafluoro borate (TBTU, 1.1 equiv). The resulting reaction mixture was stirred for 10 min then (*S*)-2–oxoazetidin–3–yl)–ammonium acetate (**9**, 1.0 equiv) was added. The reaction mixture was stirred at r.t. for 16 h, then diluted with DCM and washed with sat. NH$_4$Cl solution, sat. NaHCO$_3$ solution and brine. The organic phase

was dried over Na_2SO_4, filtered, concentrated to dryness and purified according to the specific conditions described in each example.

N–[(*S*)–2-Oxoazetidin–3–yl]–4–phenyl–butanamide (11b)—The reaction was

carried out following Method B, using salt **9** (0.060 g, 0.41 mmol), commercially available 4–phenylbutanoic acid (0.074 g, 0.45 mmol), TBTU (0.144 g, 0.45 mmol) and dry Et_3N (0.12 mL, 0.90 mmol) in dry DCM/DMF (6.0 mL). After work–up, purification by silica gel column chromatography (Cy/EtOAc, from 100:0 to 10:90) afforded compound **11b** (0.032 g, 34%), as a white solid: R_t = 1.62 min; $[\alpha]_D^{25}$=−10.8 (*c* = 0.09 in MeOH); ^{1}H NMR (400 MHz, $[D_6]$DMSO): δ 8.46 (d, 1H, *J* = 8.4 Hz,), 7.94 (bs, 1H), 7.33–7.24 (m, 2H), 7.20–7.16 (m, 3H), 4.82 (ddd, 1H, *J* = 8.4, 5.4, 2.5 Hz), 3.39 (t, 1H, *J* = 5.4 Hz), 3.03 (dd, 1H, *J* = 5.4, 2.5 Hz), 2.55 (t, 2H, *J* = 7.5 Hz), 2.12 (t, 2H, *J* = 7.5 Hz), 1.79 (p, 2H, *J* = 7.5 Hz) ppm; ^{13}C NMR (100 MHz, $[D_6]$DMSO): δ = 171.9, 168.4, 141.7, 128.9, 126.0, 125.7, 56.9, 43.1, 34.5, 34.6, 26.9 ppm; MS (ESI, *pos*) *m/z*: 233 [M+H]$^+$, 250 [M+Na]$^+$, 271 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{13}H_{17}N_2O_2$: 233.129, found: 233.1299.

5–Phenyl–*N*–[(*S*)–2–oxoazetidin–3–yl]–pentanamide (11c)—The reaction was

carried out following Method B, using salt **9** (0.050 g, 0.34 mmol), commercially available 5–phenylpentanoic acid (0.067 g, 0.38 mmol), TBTU (0.12 g, 0.38 mmol) and dry Et_3N (0.10 mL, 0.71 mmol) in dry DCM (6.0 mL). After work–up, trituration with Et_2O afforded compound **11c** (0.028 g, 33%), as a white solid: R_t = 1.79 min; $[\alpha]_D^{25}$=−40.2 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, $[D_6]$DMSO): δ 8.46 (d, 1H, *J* = 8.3 Hz), 7.94 (bs, 1H), 7.30–7.23 (m, 2H), 7.21–7.13 (m, 3H), 4.82 (ddd, 1H, *J* = 8.3, 5.4, 2.6 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.02 (dd, 1H, *J* = 5.4, 2.6 Hz), 2.56 (t, 2H, *J* = 7.2 Hz), 2.12 (t, 2H, *J* = 6.8 Hz), 1.60–1.45 (m, 4H) ppm; ^{13}C NMR (100 MHz, $[D^6]$DMSO): δ = 172.6, 168.6, 142.5, 128.7, 128.6, 126.1, 57.3, 43.31, 35.4, 35.3, 30.9, 25.2 ppm; MS (ESI, *pos*) *m/z*: 247 [M+H]$^+$, 269 [M+Na]$^+$, 285 [M+K]$^+$; MS (ESI, *neg*) *m/z*: 245 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{14}H_{19}N_2O_2$: 247.1447, found: 247.1458.

N–[(*S*)–2–Oxoazetidin–3–yl]–6–phenyl–hexanamide (11d)—The reaction was

carried out following Method B, using salt **9** (0.060 g, 0.41 mmol), commercially available 6–phenylhexanoic acid (0.084 mL, 0.45 mmol), TBTU (0.144 g, 0.45 mmol) and dry Et_3N (0.12 mL, 0.90 mmol) in dry DCM/DMF (6.0 mL). After work–up, trituration with Et_2O afforded compound **11d** (0.032 g, 30%), as a white solid: R_t = 1.98 min; $[\alpha]_D^{25}$=−12.9 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, $[D_6]$DMSO): δ 8.44 (d, 1H, *J* = 8.2 Hz), 7.94 (bs, 1H), 7.29–7.23 (m, 2H), 7.20–7.13 (m, 3H), 4.82 (ddd, 1H, *J* = 8.2, 5.4, 2.5 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.01 (dd, 1H, *J* = 5.4, 2.5 Hz), 2.58–2.52 (m, 2H), 2.08 (t, 2H, *J* = 7.4 Hz), 1.60–1.42 (m, 4H), 1.32–1.20 (m, 2H) ppm; ^{13}C NMR (100 MHz, $[D_6]$DMSO): δ = 172.5, 168.5, 142.2, 128.3, 128.2, 125.6, 56.8, 42.8, 35.5, 35.4, 30.7, 28.2, 24.9 ppm; MS (ESI, *pos*) *m/z*: 261 [M+H]$^+$, 283 [M+Na]$^+$, 299 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{15}H_{21}N_2O_2$: 261.1603, found: 261.1603.

7–Phenyl–*N*–[(*S*)–2–oxoazetidin–3–yl]–heptanamide (11e)—The reaction was

carried out following Method B, using salt **9** (0.030 g, 0.21 mmol), commercially available

7–phenylheptanoic acid (0.065 mL, 0.23 mmol), TBTU (0.073 g, 0.23 mmol) and dry Et$_3$N (0.06 mL, 0.46 mmol) in dry DCM (3.0 mL). After work–up, trituration with EtOAc

afforded compound **11e** (0.022 g, 38%), as a white solid: R$_t$ = 2.19 min; $[\alpha]_D^{25}$=−17.6 (c = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.43 (d, 1H, J = 8.4 Hz), 7.94 (bs, 1H), 7.29–7.23 (m, 2H), 7.20–7.13 (m, 3H), 4.82 (ddd, 1H, J = 8.4, 5.3, 2.6 Hz), 3.38 (t, 1H, J = 5.3 Hz), 3.02 (dd, 1H, J = 5.3, 2.6 Hz), 2.59–2.53 (m, 2H), 2.08 (t, 2H, J = 7.4 Hz), 1.60–1.42 (m, 4H), 1.32–1.21 (m, 4H) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.7, 168.6, 142.8, 128.7, 128.6, 126.0, 57.4, 43.3, 35.6, 35.5, 31.4, 28.9, 28.8, 25.5 ppm; MS (ESI, *pos*) *m/z*: 275 [M+H]$^+$, 297 [M+Na]$^+$, 313 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{16}$H$_{23}$N$_2$O$_2$: 275.1760, found: 275.1766.

(*E*)–*N*–[(*S*)–2–Oxoazetidin–3–yl]–non–3–enamide (11i)—The reaction was carried out following Method B, using salt **9** (0.050 g, 0.34 mmol), (*E*)–3–nonenoic acid (**13**) (0.058 g, 0.37 mmol), TBTU (0.12 g, 0.37 mmol) and dry Et$_3$N (0.10 mL, 0.75 mmol) in dry DCM (5.0 mL). After work–up, trituration with EtOAc afforded compound **11i** (0.035 g, 46%), as

a white solid: R$_t$ = 2.04 min; $[\alpha]_D^{25}$=−16.5 (c = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.45 (d, 1H, J = 8.4 Hz), 7.96 (bs, 1H), 5.54–5.41 (m, 2H), 4.81 (ddd, 1H, J = 8.4, 5.5, 2.6 Hz), 3.38 (t, 1H, J = 5.5 Hz), 3.03 (dd, 1H, J = 5.5, 2.6 Hz), 2.83 (d, 2H, J = 5.6 Hz), 2.01–1.93 (m, 2H), 1.37–1.19 (m, 6H), 0.86 (t, 3H, J = 7.1 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 171.0, 168.5, 133.5, 124.0, 57.3, 43.2, 39.6, 32.3, 31.3, 28.9, 22.4, 14.4; MS (ESI, *pos*) *m/z*: 225 [M+H]$^+$, 247 [M+Na]$^+$, 263 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{12}$H$_{21}$N$_2$O$_2$: 225.1603, found: 225.1614.

(*Z*)–*N*–[(*S*)–2–Oxoazetidin–3–yl]–non–3–enamide (11j)—The reaction was carried out following Method B, using salt **9** (0.050 g, 0.34 mmol), (*Z*)–non–3–enoic acid (**14**), (0.059 g, 0.38 mmol), TBTU (0.12 g, 0.38 mmol) and dry Et$_3$N (0.10 mL, 0.71 mmol) in dry DCM (3.0 mL). After work–up, trituration with EtOAc afforded compound **11j** (0.034 g,

45%), as a white solid: R$_t$ = 1.98 min; $[\alpha]_D^{25}$=−7.6 (c = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.50 (d, 1H, J = 8.3 Hz), 7.97 (bs, 1H), 5.52–5.42 (m, 2H), 4.82 (ddd, 1H, J = 8.3, 5.4, 2.5 Hz), 3.39 (t, 1H, J = 5.4 Hz), 3.03 (dd, 1H, J = 5.4, 2.5 Hz), 2.94–2.86 (m, 2H), 2.04–1.96 (m, 2H), 1.37–1.18 (m, 6H), 0.86 (t, 3H, J = 7.1 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 170.4, 168.0, 131.8, 122.9, 56.9, 42.7, 34.0, 30.8, 28.5, 26.8, 21.9, 13.9 ppm; MS (ESI, *pos*) *m/z*: 225 [M+H]$^+$, 247 [M+Na]$^+$, 263 [M+K]$^+$; MS (ESI, *neg*) *m/z*: 223 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{12}$H$_{21}$N$_2$O$_2$: 225.1603, found: 225.1612.

4–Butyl–*N*–[(*S*)–2–oxoazetidin–3–yl]–benzamide (11k)—The reaction was carried out following Method B, using salt **9** (0.060 g, 0.41 mmol), commercially available 4–butylbenzoic acid (0.080 g, 0.45 mmol), TBTU (0.144 g, 0.45 mmol) and dry Et$_3$N (0.12 mL, 0.90 mmol) in dry DCM (6.0 mL). After work–up, trituration with Et$_2$O afforded

compound **11k** (0.029 g, 29%), as a white solid: R$_t$ = 2.07 min; $[\alpha]_D^{25}$=−7.5 (c = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.99 (d, 1H, J = 8.4 Hz,), 8.02 (bs, 1H), 7.78 (d, 2H, J = 8.2 Hz), 7.29 (d, 2H, J = 8.2 Hz), 5.05 (ddd, 1H, J = 8.4, 5.4, 2.6 Hz,), 3.46 (t, 1H, J = 5.4 Hz), 3.24 (dd, 1H, J = 5.4, 2.6 Hz), 2.63 (t, 2H, J = 7.5 Hz), 1.63–1.50 (m, 2H), 1.37–1.20 (m, 2H), 0.89 (t, 3H, J = 7.4 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ

168.3, 166.0, 146.3, 131.1, 128.3, 127.4, 57.3, 42.5, 34.6, 32.8, 217, 13.7 ppm; MS (ESI, *pos*) *m/z*: 247 [M+H]$^+$, 269 [M+Na]$^+$, 285 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{14}H_{19}N_2O_2$: 247.1447, found: 247.1457.

(2*R*)- and (2*S*)-2-Methyl-*N*-[(3*S*)-2-oxoazetidin-3-yl]nonanamide (11m)—The reaction was carried out following Method B, using salt **9** (0.045 mg, 0.31 mmol), 2-methylnonanoic acid (0.059 mg, 0.34 mmol), TBTU (0.109 mg, 0.34 mmol) and dry Et$_3$N 0.090 mL, 0.68 mmol) in dry DCM (4.5 mL). After work-up, purification by silica gel flash chromatography using a Teledyne ISCO apparatus (Cy/EtOAc from 90:10 to 0:100) afforded compound **11m** (0.024 g, 32%), as a mixture (1:1 ratio) of isomers, as a trasparent liquid: R$_t$ = 2.28 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.41 (t, 2H, *J* = 8.0 Hz), 7.94 (bs, 2H), 4.85-4.78 (m, 2H), 3.44–3.36 (m, 2H), 3.01 (ddd, 2H, *J* = 8.0, 5.2, 2.7 Hz), 2.30-2.15 (m, 2H), 1.50-1.44 (m, 2H), 1.23 (s, 22H), 0.99-0.97 (m, 6H), 0.85 (t, 6H, *J* = 6.8 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 175.8, 168.2, 56.9, 43.0, 42.9, 33.8, 31.2, 29.0, 28.9, 28.7, 26.9, 26.8, 22.1, 17.9, 17.8, 14.0 ppm; MS (ESI, *pos*) *m/z*: 241 [M+H]$^+$, 258 [M+NH$_4$]$^+$, 279 [M+K]$^+$; HRMS-ESI: *m/z* [M+H]$^+$ calcd for $C_{13}H_{25}N_2O_2$: 241.1916, found: 241.1923.

2,2-Dimethyl-*N*-[(*S*)-2-oxoazetidin-3-yl]nonanamide (11n)—The reaction was carried out following Method B, using salt **9** (0.045 mg, 0.31 mmol), commercially available 2,2-dimethylnonanoic acid (0.064 mg, 0.34 mmol), TBTU (0.144 g, 0.45 mmol) and dry Et$_3$N (0.090 mL, 0.68 mmol) in dry DCM/DMF (3:1, 4.4 mL). After work-up, purification by preparative HPLC afforded compound **11n** (0.026 g, 33%), as a trasparent liquid: R$_t$ = 2.47 min; $[\alpha]_D^{25}$=−3.50 (*c* = 0.10 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO) δ 8.01 (d, 1H, *J* = 8.4 Hz), 7.88 (bs, 1H), 4.79 (ddd, 1H, *J* = 8.4, 5.4, 2.8 Hz), 3.34 (t, 1H, *J* = 5.4 Hz), 3.09 (dd, 1H, *J* = 5.4, 2.8 Hz), 1.45–1.36 (m, 2H), 1.29-1.07 (m, 10H), 1.04 (s, 6H), 0.84 (t, 3H, *J* = 6.9 Hz); ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 177.0, 168.6, 57.1, 42.4, 41.5, 40.6, 31.3, 29.6, 28.7, 25.3, 25.2, 24.2, 22.1, 14.0 ppm; MS (ESI, *pos*) *m/z*: 255 [M+H]$^+$, 272 [M+NH$_4$]$^+$, 277 [M+Na]$^+$; HRMS-ESI: *m/z* [M+H]$^+$ calcd for $C_{14}H_{27}N_2O_2$: 255.2073, found: 255.2084.

***N*–[(*S*)–2–Oxoazetidin–3–yl]–undecanamide (11p)—**The reaction was carried out following Method B, using salt **9** (0.060 g, 0.41 mmol), commercially available undecanoic acid (0.084 g, 0.45 mmol), TBTU (0.144 g, 0.45 mmol) and dry Et$_3$N (0.12 mL, 0.90 mmol) in dry DCM (6.0 mL). After work–up, trituration with EtOAc afforded compound **11p** (0.065 g, 62%), as a white solid: R$_t$ = 2.54 min; $[\alpha]_D^{25}$=−15.6 (*c* = 0.08 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.43 (d, 1H, *J* = 8.3 Hz), 7.94 (bs, 1H), 4.82 (ddd, 1H, *J* = 8.3, 5.4, 2.5 Hz), 3.38 (t, 1H, *J* = 5.4 Hz), 3.02 (dd, 1H, *J* = 5.4, 2.5 Hz), 2.08 (t, 2H, *J* = 7.4 Hz), 1.54–1.42 (m, 2H), 1.33–1.18 (m, 14H), 0.84 (t, 3H, *J* = 6.4 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ 172.3, 168.2, 55.9, 42.9, 35.2, 31.3, 29.0, 28.9, 28.8, 28.7, 28.6, 25.1, 22.1, 14.0 ppm; MS (ESI, *pos*) *m/z*: 255 [M+H]$^+$, 293 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for $C_{14}H_{27}N_2O_2$: 255.2073, found: 255.2083.

6–Cyclohexyl–*N*–[(*S*)–2–oxoazetidin–3–yl]–hexanamide (11q)—The reaction was carried out following Method B, using salt **9** (0.050 g, 0.34 mmol), 7-cyclohexylheptanoic

acid (**15**) (0.08 g, 0.38 mmol), TBTU (0.12 g, 0.38 mmol) and dry Et$_3$N (0.100 mL, 0.75 mmol) in dry DCM (6.0 mL). After work–up, trituration with Et$_2$O afforded compound **11q** (0.033 g, 35%), as a white solid: R$_t$ = 2.73 min; $[\alpha]_D^{25}$=−14.5 (c = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ = 8.42 (d, 1H, J = 8.3 Hz), 7.94 (bs, 1H), 4.85–4.79 (m, 1H), 3.38 (t, 1H, J = 5.3 Hz), 3.02 (dd, 1H, J = 5.3, 2.7 Hz), 2.08 (t, 2H, J = 7.4 Hz), 1.70–1.55 (m, 5H), 1.53–1.42 (m, 2H), 1.28–1.07 (m, 12H), 0.89–0.77 (m, 2H) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO) δ = 172.7, 168.6, 57.3, 43.3, 37.5, 37.4, 35.6, 33.4, 29.6, 29.1, 26.7, 26.6, 26.3, 25.5 ppm; MS (ESI, *pos*) *m/z*: 281 [M+H]$^+$, 303 [M+Na]$^+$, 319 [M+K]$^+$; MS (ESI, *neg*) *m/z*: 279 [M–H]$^-$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{16}$H$_{29}$N$_2$O$_2$: 281.2229, found: 281.2237.

N–(2–Oxocyclobutyl)nonanamide (21h)—Under nitrogen atmosphere, amide **25** (0.210 g, 1.34 mmol) was dissolved in dry THF (15.0 mL) and commercially available 2N HCl–Et$_2$O solution (15.0 mL) was added at 0 °C. Then, commercially available bis(trimethylsilyloxy) cyclobutene (0.33 mL, 1.27 mmol) was added in one portion. The solution was refluxed for 3 h and then concentrated to dryness. Purification by typical silica flash chromatography (Cy/EtOAc, 60:40) and preparative HPLC afforded compound **21h** (0.110 g, 37%), as a white solid: R$_t$ = 2.48 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.27 (d, 1H, J = 7.9 Hz), 4.77 (dt, 1H, J = 10.3, 7.9 Hz), 2.93–2.80 (m, 1H), 2.79–2.68 (m, 1H), 2.19 (qd, 1H, J = 10.3, 4.5 Hz), 2.06 (t, 2H, J = 7.3 Hz), 2.02–1.91 (m, 1H), 1.52–1.40 (m, 2H), 1.32–1.17 (m, 10H), 0.86 (t, 3H, J = 6.8 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 207.5, 172.3, 64.0, 41.6, 35.2, 31.7, 29.2, 29.1, 29.0, 25.5, 22.5, 18.8, 14.4 ppm. MS (ESI, *pos*) *m/z*: 226 [M+H]$^+$, 248 [M+Na]$^+$, 264 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{13}$H$_{24}$NO$_2$: 226.1807, found: 226.1814.

N–(Azetidin–3–yl)nonanamide (22h)—To a cooled (0 °C), stirred solution of Boc-derivative **26** (0.060 g, 0.19 mmol) in DCM (3.0 mL), a 1:3 mixture of TFA/DCM (4.0 mL) was added dropwise The reaction mixture was stirred at 0 °C for 30 min, then at r.t. for additional 30 min. The solution was diluted with sat. Na$_2$CO$_3$ solution until neutralization. The organic phase was separated and the aqueous phase was extracted from DCM (15.0 mL) and EtOAc (15.0 mL). The combined organic phases were dried over Na$_2$SO$_4$, filtered and concentrated to dryness, affording compound **22h** (0.095 g, quant.), as a colorless oil: R$_t$ = 1.92 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ = 8.62 (bs, 1H), 8.50 (d, 1H, J = 6.5 Hz), 4.55 (sex, 1H, J = 15.1, 7.6 Hz), 4.11–4.04 (m, 1H), 3.92–3.85 (m, 1H), 2.08 (t, 2H, J = 7.4 Hz), 1.55–1.40 (m, 2H), 1.32–1.17 (m, 10H), 0.86 (t, 3H, J = 6.8 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.9, 52.6, 41.4, 35.6, 31.7, 29.2, 29.1, 29.0, 25.4, 22.5, 14.4 ppm; MS (ESI, *pos*) *m/z*: 213 [M+H]$^+$, 235 [M+Na]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{12}$H$_{25}$N$_2$O: 213.1967, found: 213.1977.

[(S)–3–Hydroxy–2–(nonanoylamino)–3–oxo–propyl]ammonium chloride (23h)—β–lactam amide **11h** (0.040 g, 0.18 mmol) was suspended in 2N HCl (3.0 mL) and it was vigorously stirred at room temperature for 30 min, then THF (2.0 mL) was added to the suspension to dissolve any insoluble residue. The resulting solution was stirred at room temperature for 16 h. Solvents were evaporated. Trituration with EtOAc afforded compound **23h** (0.040 g, 79%), as a white solid: R$_t$ = 1.68 min; $[\alpha]_D^{25}$=−10.0 (c = 0.11 in MeOH); ^{1}H

NMR (400 MHz, [D$_6$]DMSO): δ 13.00 (bs, 1H), 8.31 (d, 1H, J = 8.0 Hz), 8.17 (bs, 3H), 4.47 (dt, 1H, J = 8.0, 5.2 Hz), 3.19 (dd, 1H, J = 13.0, 5.2 Hz), 3.00 (dd, 1H, J = 13.0, 8.9 Hz), 2.15 (t, 2H, J = 7.6 Hz), 1.56–1.46 (m, 2H), 1.33–1.19 (m, 10H), 0.90–0.82 (m, 3H) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 173.4, 171.3, 50.4, 35.7, 31.7, 29.3, 29.1, 25.4, 22.6, 14.4 ppm; MS (ESI, *pos*) *m/z:* 245 [M+H]$^+$, 267 [M+Na]$^+$, 283 [M+K]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{12}$H$_{25}$N$_2$O$_3$: 245.1865, found: 245.1873.

N-[(3*S*)-2-Oxopyrrolidin-3-yl]-nonanamide (24h)

The reaction was carried out following Method A, using commercially available (3S)-3-aminopyrrolidin-2-one (0.100 g, 1.0 mmol), commercially available nonanoyl chloride (0.24 mL, 1.10 mmol) and dry Et$_3$N (0.15 mL, 1.10 mmol) in dry DCM (8 mL). After work-up, trituration with Et$_2$O afforded compound **24h** (0.20 g, 83%), as a white solid: R$_t$ = 2.09 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 7.99 (d, 1H, J = 8.3 Hz), 7.76 (bs, 1H), 4.27 (dt, 1H, J = 10.3, 8.3 Hz), 3.20-3.11 (m, 2H), 2.32-2.23 (m, 1H), 2.07 (t, 2H, J = 7.4 Hz), 1.81-1.69 (m, 1H), 1.53-1.43 (m, 2H), 1.31-1.20 (m, 10H), 0.85 (t, 3H, J = 6.6 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 174.5, 172.2, 49.3, 38.0, 35.2, 31.2, 28.7, 28.6, 28.5, 25.2, 22.1, 13.9 ppm; MS (ESI, *pos*) *m/z:* 241 [M+H]$^+$; MS (ESI, *neg*) *m/z:* 239 [M–H]$^-$; HRMS-ESI: *m/z* [M +H]$^+$ calcd for C$_{13}$H$_{25}$N$_2$O$_2$: 241.1916, found: 241.192.

N-[(*S*)-1-methyl-2-oxo-azetidin-3-yl]nonanamide (27h)

Under nitrogen atmosphere, to a cooled (0° C) solution of amide **11h** in dry THF (2.5 mL), a suspension of NaH (60% mineral oil, 0.015 g, 0.362 mmol) in dry THF (4.0 mL) was added dropwise. The mixture was warmed up to r.t., stirred for additional 20 min and cooled again to 0°C. MeI (0.022 mL, 0.362 mmol) was added dropwise and the resulting reaction mixture was maintained at 0°C for 3 h, warmed up to r.t. and stirred for additional 2 h and 30 min. The reaction mixture was diluted with DCM (25 mL), and water (2.0 mL). The aqueous layer was extracted with DCM (3 x10 mL) and the combined organic layers were dried over Na$_2$SO$_4$, filtered and concentrated to dryness. Purification by preparative HPLC afforded pure compound **27h** (0.020 g, 25% yield), as a white solid: R$_t$ = 2.23 min; $[\alpha]_D^{25}$=−6.7 (*c* = 0.07 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ = 8.42 (d, 1H, J = 8.1 Hz), 4.81 (ddd, 1H, J = 8.1, 5.2, 2.4 Hz), 3.46 (t, 1H, J = 5.2 Hz), 3.08 (dd, 1H, J = 5.2, 2.4 Hz), 2.73 (s, 3H), 2.07 (t, 2H, J = 7.4 Hz), 1.55–1.42 (m, 2H), 1.33–1.17 (m, 10H), 0.86 (t, 3H, J = 6.8 Hz); ^{13}C NMR (100 MHz, [D$_6$]DMSO: 172.2, 167.1, 56.0, 49.0, 35.1, 31.2, 28.7, 28.6, 28.5, 28.1, 25.1, 22.1, 13.9 ppm; MS (ESI, *pos*) *m/z:* 241 [M+H]$^+$, 263 [M+Na]$^+$, 279 [M+K]$^+$; HRMS-ESI: *m/z* [M+H]$^+$ calcd for C$_{13}$H$_{25}$N$_2$O$_2$: 241.1916, found: 241.1918

N–Methyl–*N*–[(*S*)–2–oxoazetidin–3–yl]–nonanamide (28h)

The reaction was carried out following Method A, using salt **31** (0.050 g, 0.31 mmol), commercially available nonanoyl chloride (0.076 mL, 0.34 mmol) and dry Et$_3$N (0.091 mL, 0.66 mmol) in dry DCM (5.0 mL). After work–up, purification by preparative HPLC afforded compound **28h** (0.027 g, 33%), as a 1:1 mixture of two rotamers, as an oil: R$_t$ = 2.31 min; $[\alpha]_D^{25}$=−16.3 (*c* = 0.12 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 8.14 (bs, 1H), 8.07 (bs, 1H), 5.50–5.45 (m, 1H), 5.33–5.27 (m, 1H), 3.43 (t, 1H, J = 5.8 Hz), 3.35 (t, 1H, J = 5.8 Hz), 3.22 (dd, 1H, J = 5.8, 2.5 Hz), 3.17 (dd, 1H, J = 5.8, 2.5 Hz), 2.90 (s, 3H), 2.74 (s, 3H), 2.42–2.23 (m,

4H), 1.53–1.40 (m, 4H), 1.33–1.16 (m, 20H), 0.86 (t, 6H, J = 7.0 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 172.6, 172.2, 167.4, 166.8, 64.6, 62.0, 32.6, 32.4, 31.4, 31.2, 28.8, 28.7, 28.6, 28.0, 24.9, 24.4, 22.1, 14.0 ppm; MS (ESI, *pos*) *m/z:* 241 [M+H]$^+$, 263 [M+Na]$^+$, 279 [M+K]$^+$; HRMS–ESI: m/z [M+H]$^+$ calcd for C$_{13}$H$_{25}$N$_2$O$_2$: 241.1916, found: 241.1918.

(*S*)–3–(Nonylamino)azetidin–2–one (32)—Under nitrogen atmosphere, to a stirred suspension of salt **9** (0.050 g, 0.34 mmol) in dry dichloroetane (3.5 mL), dry Et$_3$N (0.050 mL, 0.38 mmol) was added. The resulting suspension was stirred for 10 min, then a solution of aldehyde **35** (0.049 g, 0.34 mmol) in dry dichloroetane (0.5 mL) and Na(OAc)$_3$BH (0.100 g, 0.48 mmol) were added to the reaction mixture. The solution was stirred for 90 min, then diluted with EtOAc (20.0 mL) and washed with sat. NaHCO$_3$ solution (10.0 mL). The organic phase was dried over Na$_2$SO$_4$, filtered and concentrated to dryness. Purification by typical silica flash chromatography (DCM/MeOH, from 97:3 to 95:5) afforded compound **32** (0.015 g, 21%), as a white solid: R$_t$ = 2.37 min; ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 7.72 (bs, 1H), 4.00 (bs, 1H), 3.24 (t, 1H, J = 5.2 Hz), 2.92 (dd, 1H, J = 5.6, 2.4 Hz), 2.63–2.52 (m, 2H), 1.42–1.16 (s, 14H), 0.86 (d, 3H, J = 7.0 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 168.5, 67.5, 46.5, 43.0, 31.8, 30.3, 29.5, 29.4, 29.1, 27.2, 22.6, 14.4 ppm; MS (ESI, *pos*) *m/z*: 213 [M+H]$^+$, 235 [M+Na]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{12}$H$_{25}$N$_2$O: 213.1967, found: 213.1977.

1–Heptyl–3–[(*S*)–2–oxoazetidin–3–yl]–urea (33)—To a solution of salt **9** (0.047 g, 0.32 mmol) in dry pyridine (4.0 mL), DMAP (0.048 g, 0.39 mmol) and, subsequently, heptyl isocyanate (0.057 mL, 0.36 mmol) were added. The reaction mixture was stirred at r.t. for 16 h and concentrated to dryness. Trituration with DCM afforded compound **33** (0.040 g, 59%), as a white solid: R$_t$ = 1.90 min; $[\alpha]_D^{25}$=+2.07 (*c* = 0.08 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 7.83 (bs, 1H), 6.50 (d, 1H, J = 8.4 Hz), 5.94 (t, 1H, J = 5.4 Hz), 4.80–4.63 (m, 1H), 3.34 (t, 1H, J = 5.4 Hz), 3.03–2.99 (m, 1H), 2.99–2.92 (m, 2H), 1.31–1.14 (m, 10H), 0.94–0.81 (m, 3H) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 169.4, 157.0, 57.9, 43.8, 31.3, 29.9, 28.4, 26.3, 22.0, 13.9 ppm; MS (ESI, *pos*) *m/z*: 228 [M+H]$^+$, 250 [M+Na]$^+$; HRMS–ESI: *m/z* [M+H]$^+$ calcd for C$_{11}$H$_{22}$N$_3$O$_2$: 228.1712, found: 228.1718.

Heptyl *N*–[(*S*)–2–oxoazetidin–3–yl]–carbamate (34)—Under nitrogen atmosphere, to a suspension of salt **9** (0.040 g, 0.27 mmol) in dry DCM (4.0 mL), DIPEA (0.053 mL, 0.32 mmol) was added dropwise. Subsequently, the crude mixture (0.179 g) containing **37** (0.064 g, 0.27 mmol) in dry DCM (2.0 mL) was added. The reaction mixture was stirred at r.t. for 15 h, then concentrated to dryness. Purification by typical silica gel flash chromatography (Cy/EtOAc, from 100:0 to 40:60) afforded compound **34** (0.022 g, 36%), as a white solid: R$_t$ = 2.18 min; $[\alpha]_D^{25}$=−15.1 (*c* = 0.05 in MeOH); ^{1}H NMR (400 MHz, [D$_6$]DMSO): δ 7.90 (bs, 1H), 7.78 (d, 1H, J = 8.6 Hz), 4.58–4.62 (m, 1H), 3.95 (t, 2H, J = 6.7 Hz), 3.37 (t, 1H, J = 5.4 Hz), 3.07 (dd, 1H, J = 5.4, 2.7 Hz), 1.59–1.48 (m, 2H), 1.35–1.21 (m, 8H), 0.86 (t, 3H, J = 6.9 Hz) ppm; ^{13}C NMR (100 MHz, [D$_6$]DMSO): δ = 168.2, 155.6, 64.1, 58.3, 42.6, 31.2, 28.6, 28.3, 25.3, 22.0, 13.9 ppm; MS (ESI, *pos*) *m/z*: 229 [M+H]$^+$, 251 [M+Na]$^+$, 267 [M+K]$^+$; HRMS–ESI: *m/z* [M+Na]$^+$ calcd for C$_{11}$H$_{20}$N$_2$O$_3$Na: 251.1372, found: 251.1374.

Pharmacology

Fluorogenic h-NAAA Assay—Hek293 cells stably transfected with the human NAAA coding sequence cloned from a human spleen cDNA library were used as enzyme source. Recombinant HEK-*h*-NAAA pellets were resuspended in homogenizing buffer, and sonicated. Samples were spinned at 800×g for 15 min at 4°C and the resultant supernatants were then ultracentrifuged at 12,000×g for 30 min at 4°C. The pellets were resuspended in PBS pH 7.4 on ice and subjected to two freeze/thaw cycles at −80°C. The suspension was finally centrifuged at 105,000×g for 1 h at 4°C. Protein concentration was measured and samples aliquoted and stored at −80°C until use. The assay was run in Optiplate 96-wells black plates (Perkin Elmer Inc., Boston, MA, USA), in a total reaction volume of 200 μL. NAAA protein preparation (20 μg) was pre-incubated for 10 min with various concentrations of test compounds or vehicle control (5 % DMSO) in 100 mM citrate/ phosphate buffer (pH 4.5) containing 3 mM DTT, 0,1 % Triton X-100, 0,05 % BSA, 150 mM NaCl. *N*-(4-methyl-2-oxo-chromen-7-yl)-hexadecanamide (PAMCA)[16] was used as a substrate (5 μM) and the reaction carried over for 30 min at 37°C. The samples were then read in a Perkin Elmer Envision plate reader (Perkin Elmer Inc., Boston, MA, USA) using an excitation wavelength of 360 nm and emission 460 nm. IC_{50} values were calculated by non-linear regression analysis of log[concentration]/inhibition curves using GraphPad Prism 5 (GraphPad Software Inc., CA–USA) applying a standard slope curve fitting.

In vitro chemical stability—Chemical stability of selected compounds was evaluated under physiological pH conditions (0.01 M phosphate-buffered saline, pH 7.4) and acidic pH conditions (0.01 M phosphate buffer, pH 5.0) for up to 24 h. Both buffers were added with 10% of CH_3CN. Stock solutions of each compound (10 mM) were prepared freshly in DMSO. Each compound was incubated at a final concentration of 1 μM (1% DMSO) in both preheated buffers (37°C). The sample solutions were divided into aliquots in glass vials (preheated at 37°C) for each time point. The samples were maintained at 37°C in the UPLC-MS autosampler during the study (no shaking). A reference solution of each compound (final concentration: 1 μM at 1% DMSO) in preheated CH_3CN (37°C) was prepared from the stock solutions (10 mM in DMSO) and maintained at 37°C in the UPLC-MS autosampler during the study (no shaking). The analyses were performed on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (triple quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. The 24 h time course analysis for **1**, **11a** and **11h** was carried out by UPLC-UV on the same instrument described above. A calibration curve in the 0.2–50 μM concentration range was prepared for each parent compound by serial dilution in CH_3CN (R^2 values were > 0.999 for all compounds). The concentration of the rearranged and hydrolyzed products of each parent was then calculated on the corresponding calibration curve, assuming no changes in the molar absorptivity values (ε). To test this assumption, each parent was fully hydrolyzed with 1 M NaOH solution and the concentration of the corresponding product was calculated on the parent compound calibration curve. The measured concentration matched the expected 30 μM value. The analyses were run on an ACQUITY UPLC BEH C18 1.7 μm 2.1 × 50mm column with a VanGuard BEH C18 1.7μm pre-column at 40 °C. The mobile phase was 0.1% HCOOH in H_2O (A) and 0.1% HCOOH in CH_3CN (B) using

the following gradient: 0–0.5 min.: 5% B, 0.5-2.5 min.: 5-100% B, 2.5-2.7 min.: 100% B, 2.7-2.8 min.: 100-5% B, 2.8-3.5: 5%B with flow rate at 0.5 mL/min.

In vitro mouse plasma stability—Compounds were diluted in mouse plasma added with 5% DMSO to help solubilization. Plasma was already pre-heated at 37° C (10 min). The final compound concentration was 2 μM. At time points (immediately after dilution, 5, 15, 30, 60, 120, min) a 40 μL aliquot of the incubation solution was diluted in 120 μL of cold CH_3CN spiked with Warfarin 200 nM, as internal standard. After 30 sec of vortexing, the solution was centrifuged at 3500g for 15 min at 4°C and the surnatant transferred for LC-MS analysis on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) Mass Spectrometer equipped with an Electrospray Ionization interface. Briefly: 3 μL of the surnatant were injected on a reversed phase column (BEH C18 2.1X50 mm) and separated with a linear acetonitrile gradient. Compounds were quantified on the basis of their MRM (Multiple Reaction Monitoring) peak areas. The response factors, calculated on the basis of the internal standard peak area, were then plotted over time. When possible, response vs time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compound half lives in plasma.

In vitro rat plasma stability—Compounds were added to blank rat plasma pre-incubated at 37°C. Final molecule concentration was 2 μM. Final DMSO concentration was 2.5%. The mixture was kept at 37°C under shaking. Aliquots (50 μL) were taken at various timepoints (0, 5, 15, 30, 60 and 120 minutes) and crashed with 150μL of acetonitrile spiked with 200 nM warfarin (internal standard). After vortexing and centrifugation, 3 μL of surnatant were analyzed by LC-MS/MS by multiple reaction monitoring (MRM). The corresponding time Vs response factor profiles were fitted with PRISM (Graphpad, CA, USA) to derive the experimental half-life of the compounds.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. a) Calignano A, La Rana G, Giuffrida A, Piomelli D. Nature. 1998; 394:277–281. [PubMed: 9685157] b) LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. Life Sci. 2005; 77:1685–1698. [PubMed: 15963531]

2. Piomelli D, Giuffrida A, Calignano A, de Fonseca FR. Trends Pharmacol Sci. 2000; 21:218–224. [PubMed: 10838609]

3. a) Berdyshev E, Boichot E, Corbel M, Germain N, Lagente V. Life Sci. 1998; 63:Pl125–Pl129. [PubMed: 9718090] b) D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Raso GM, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A. J Pharmacol Exp Ther. 2007; 322:1137–1143. [PubMed: 17565008]

4. a) Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. Eur J Pharmacol. 1996; 300:227–236. [PubMed: 8739213] b) Calignano A, La Rana G, Piomelli D. Eur J Pharmacol. 2001; 419:191–198. [PubMed: 11426841] c) Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, Sorrentini I, Di Marzo V. Neuropharmacology. 2005; 48:1154–1163. [PubMed: 15910891]

5. a) Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. Mol Pharmacol. 2005; 67:15–19. [PubMed: 15465922] b) LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. J Pharmacol Exp Ther. 2006; 319:1051–1061. [PubMed: 16997973] c) Khasabova IA, Xiong Y, Coicou LG, Piomelli D, Seybold V. J Neurosci. 2012; 32:12735–12743. [PubMed: 22972997]

6. a) Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tuting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. Allergy. 2010; 65:698–711. [PubMed: 19909294] b) Kemeny L, Koreck A, Kis K, Kenderessy-Szabo A, Bodai L, Cimpean A, Paunescu V, Raica M, Ghyczy M. Skin Pharmacol Phys. 2007; 20:155–161.c) Hesselink JM, Hekker TA. J Pain Res. 2012; 5:437–442. [PubMed: 23166447]

7. Piomelli D. Trends Endocrin Met. 2013; 24:332–341.

8. Leung D, Saghatelian A, Simon GM, Cravatt BF. Biochemistry-Us. 2006; 45:4720–4726.

9. a) Ueda N, Yamanaka K, Yamamoto S. J Biol Chem. 2001; 276:35552–35557. [PubMed: 11463796] b) Tsuboi K, Takezaki N, Ueda N. Chem Biodivers. 2007; 4:1914–1925. [PubMed: 17712833]

10. Ueda N, Tsuboi K, Uyama T. Prog Lipid Res. 2010; 49:299–315. [PubMed: 20152858]

11. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. J Biol Chem. 2005; 280:11082–11092. [PubMed: 15655246]

12. a) Tsuboi K, Zhao LY, Okamoto Y, Araki N, Ueno M, Sakamoto H, Ueda N. Biochim Biophys Acta Mol Cell Biol Lipids. 2007; 1771:623–632.b) Tsuboi K. Inflamm Regener. 2007; 27:18–27.

13. Zhao LY, Tsuboi K, Okamoto Y, Nagahata S, Ueda N. Biochim Biophys Acta Mol Cell Biol Lipids. 2007; 1771:1397–1405.

14. Rossocha M, Schultz-Heienbrok R, von Moeller H, Coleman JP, Saenger W. Biochemistry-Us. 2005; 44:5739–5748.

15. Wang J, Zhao LY, Uyama T, Tsuboi K, Tonai T, Ueda N. Biochim Biophys Acta Mol Cell Biol Lipids. 2008; 1781:710–717.

16. West JM, Zvonok N, Whitten KM, Wood JT, Makriyannis A. J Proteome Res. 2012; 11:972–981. [PubMed: 22040171]

17. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Brit J Pharmacol. 2011; 163:1479–1494. [PubMed: 21175579]

18. a) Vandevoorde S, Tsuboi K, Ueda N, Jonsson KO, Fowler CJ, Lambert DM. J Med Chem. 2003; 46:4373–4376. [PubMed: 14521402] b) Tsuboi K, Hilligsmann C, Vandevoorde S, Lambert DM, Ueda N. Biochem J. 2004; 379:99–106. [PubMed: 14686878] c) Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, Di Marzo V. Bioorg Med Chem Lett. 2010; 20:1210–1213. [PubMed: 20022504] d) Yamano Y, Tsuboi K, Hozaki Y, Takahashi K, Jin XH, Ueda N, Wada A. Bioorg Med Chem. 2012; 20:3658–3665. [PubMed: 22542283] e) Li Y, Yang L, Chen L, Zhu C, Huang R, Zheng X, Qiu Y, Fu J. Plos One. 2012; 7:1–7.

19. Solorzano C, Zhu CG, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. P Natl Acad Sci USA. 2009; 106:20966–20971.Solorzano C, Antonietti F, Duranti A, Tontini A, Rivara S, Lodola A, Vacondio F, Tarzia G, Piomelli D, Mor M. J Med Chem. 2010; 53:5770–5781. [PubMed: 20604568] Duranti A, Tontini A, Antonietti F, Vacondio F, Fioni A, Silva C, Lodola A, Rivara S, Solorzano C, Piomelli D, Tarzia G, Mor M. J Med Chem. 2012; 55:4824–4836. [PubMed: 22515328] Ponzano S, Bertozzi F, Mengatto L, Dionisi M, Armirotti A, Romeo E, Berteotti A, Fiorelli C, Tarozzo G, Reggiani A, Duranti A, Tarzia G, Mor M, Cavalli A, Piomelli D, Bandiera T. J Med Chem. 2013; 56:6917–6934. [PubMed: 23991897] Vitale R, Ottonello G, Petracca R, Bertozzi SM, Ponzano S, Armirotti A, Berteotti A, Dionisi M, Cavalli A, Piomelli D, Bandiera T, Bertozzi F. Chem Med Chem. 2014; 9:323–336. [PubMed: 24403170] f) Compounds **1** and **2** were tested using the reported assay conditions, giving $IC_{50} = 1.29 \pm 0.215$ μM and $IC_{50} = 0.047 \pm 0.005$ μM, respectively.

20. Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D. Pain. 2013; 154:350–360. [PubMed: 23218523]

21. 3-Aminoazetidin-2-one has been described in Matsuo T, Masuya YK, Noguchi N, Ochiai M. Chem Pharm Bull. 1983; 31:1874–1884. [PubMed: 6640788]

22. Hanessian S, Couture C, Wiss H. Can J Chem. 1985; 63:3613–3617.Deprotection of benzyl N-(2-oxoazetidin-3-yl) carbamate was adapted from Felix AM, Lambros TJ, Tzougraki C, Meienhofer J. J Org Chem. 1978; 33:4194–4196.. Other deprotection procedures on the same substrate were reported in Nakaguchi O, Hemmi K, Shiokawa Y, Hashimoto M, Kamiya T. Chem Pharm Bull. 1987; 35:3464–3466. [PubMed: 3427723]

23. All the intermediates were obtained in almost pure form after simple work-up and/or trituration with solvent.

24. The use of EtOH as protic solvent turned out to be critical for the reaction.

25. McGinley CM, Jacquot C, van der Donk WA. Bioorg Med Chem Lett. 2007; 17:4049–4052. [PubMed: 17485208]

26. 5-Cyclohexylpentan-1-ol **23** was obtained starting from the corresponding commercially available carboxylic acid by standard reduction.

27. a) Ghosh AK, Duong TT, Mckee SP. Tetrahedron Lett. 1991; 32:4251–4254.b) Shiina I, Suenaga Y, Nakano M, Mukaiyama T. Bull Chem Soc Jpn. 2000; 73:2811–2818.

28. The in vivo *h*-NAAA inhibitory assay was performed at pH 5.0.

29. Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D. Sci Rep-UK. 2013; 310.1038/srep01035

Figure 1.
Structures of (S)–OOPP (**1**) and ARN077 (**2**)

azetidin-2-one scaffold essential for activity

R = long, flexible alkyl chain preferred

X = CH$_2$, O well tolerated

S configuration strongly preferred

Figure 2.
Summary of key structural features for β-lactam based inhibitors of NAAA.

Scheme 1.

Synthetic pathway for the preparation of amide derivatives **11a–q** and **12h.** *Reagents and conditions*: a) *p*–anisidine, EDC, THF/DCM (3:1), r.t., 16 h [85–92%]; b) ImSO$_2$Im, 0 °C, 1 h, then NaH, DMF, −20 °C, 1 h [75%]; c) CAN, MeCN/H$_2$O (1:1), 0 °C, 1 h [80–85%]; d) 1,4–cyclohexadiene, 10% Pd on charcoal, EtOH, r.t., 12 h, then AcOH, EtOAc [79%]; Method A [for **11a, 11f**–**h**, **11l**, **11o** and **12h**]: RCOCl, Et$_3$N, DCM or DCM/DMF (3:1), r.t., 16 h [15–65%]; Method B [for **11b**–**e**, **11i**–**k**, **11m**–**n** and **11p**–**q**]: RCOOH, TBTU, Et$_3$N, DCM/DMF (3:1), r.t., 16 h [30–62%].

Scheme 2.
Syntheses of carboxylic acids **13, 14** and **15**. *Reagents and conditions*: a) LiOH, THF/MeOH/H$_2$O (1:1:1), r.t., 1 h [quant.]; b) Dess–Martin Periodinane, DCM, 0 °C, 1 h, then r.t, 1 h. [94%]; c) NaClO$_2$, NaH$_2$PO$_4$, 2–methyl–2–butene, *t*BuOH/H$_2$O 4:1, r.t. 1.5 h [quant.]; d) DMSO, oxalyl chloride, DCM, −78°C, 15 min then **17**, −78 °C, 1 h, then Et$_3$N, r.t. [quant.]; e) (EtO)$_3$POCH$_2$CO$_2$Et, NaH (95%), THF, 0 °C to r.t. [77%]; f) H$_2$, 10% Pd/C cartridge (H–Cube®, EtOH, 45 °C, 20 bar, flow: 1.0 mL/min), 92%; g) LiOH, THF/MeOH/H$_2$O (1:1:1), r.t., 1 h [quant.].

Scheme 3.

Syntheses of compounds **21h-24h**. *Reagents and conditions*: a) 1N NaOH, 35%, H_2O_2, 60% *t*BuOH–H_2O, r.t., 16 h [82%]; b) 2N HCl.Et_2O, 1,2–bis(trimethylsiloxy)cyclobutene, THF, reflux, 3 h [37%]; c) nonanoyl chloride, Et_3N, DCM, r.t., 2 h [94%]; d) TFA/DCM (1:3), 0 °C, 30 min, then r.t. 45 min [quant.]; e) 2N HCl, r.t., 30 min then THF, r.t., 16 h [79%]; Method A: nonanoyl chloride, Et_3N, DCM, r.t., 16 h [83%].

Scheme 4.
Syntheses of *N*–methylated compounds **27h-28h**. *Reagents and conditions*: a) NaH (60% in mineral oil), MeI, THF, 0° C, 1 h then r.t., 4 h [25%]; b) NaH (95%), MeI, THF, 0° C, 1 h then r.t., 1 h [90%]; c) CAN, MeCN/H_2O (1:1), 0 °C, 1 h [92%]; d) H_2, 10% Pd/C cartridge (H–Cube, EtOAc, 30 °C, 1.0 bar, flow: 1.0 mL/min) then AcOH, EtOAc [78%]; Method A: nonanoyl chloride, Et_3N, DCM, r.t., 16 h [33%].

Scheme 5.
Syntheses of amine, urea and carbamate derivatives **32–34.** *Reagents and conditions*: a)
DMSO, oxalyl chloride, DCM, −78 °C, 15 min then *n*–nonanol −78 °C, 1 h, then Et₃N, r.t.
[quant.]; b) **9**, Et₃N, dichloroethane, 10 min, then Na(OAc)₃BH, r.t., 1.5 h [21%]; c) nonyl
isocyanate, DMAP, pyridine, r.t., 16 h [59%]; d) DMAP, 2-DPC, DCM, r.t., 16 h [quant.]; e)
9, DIPEA, DCM, r.t., 16 h [36%].

Table 1

Inhibitory potencies (IC$_{50}$) on human NAAA of compounds **11a–h**[a]

| Compounds	Structure	h–NAAA IC$_{50}$ (μM) ± S.E.M
11a		Not active[b]
11b		73.36 ± 10.68
11c		27.16 ± 1.89
11d		12.06 ± 2.18
11e		0.60 ± 0.17
11f		27.02 ± 6.15
11g		1.91 ± 0.28
11h		0.34 ± 0.03

[a] IC$_{50}$ values are reported as mean values of three or more determinations.

[b] Not active: < 10% inhibition @ 50 μM.

Table 2

Stability data of (*S*)–OOPP (**1**) and compounds **11a**, **11h**.

Cmpd	Chemical Stability[a],		m–Plasma Stability[a,c]	r–Plasma Stability[a,e]
	pH 7.4, $t_{1/2}$ (min), (%)[d]	pH 5.0, $t_{1/2}$ (min)[d]	$t_{1/2}$ (min)	$t_{1/2}$ (min)
1	30	45	<1	n.t.[f]
11a	>1440 (*92*)	>1440 (*97*)	>120	>120
11h	>1440 (*100*)	>1440 (*98*)	103	>120

[a] Stability values are reported as mean values of three or more determinations.

[b] Measured after 24 h of incubation at 37 °C in PBS + 10% MeCN at pH 7.4 and 5.0; values in parentheses represent the compound remaining (%) after 24 h (1440 min)

[c] Measured in 100% mouse plasma.

[d] Compound remaining (%) after 24 h (1440 min).

[e] Compounds tested at 2.5 μM in *r*-plasma added with 2.5% DMSO.

[f] n.t. = Not tested. Compound **1** was reported to have $t_{1/2}$ < 10 sec in 80% *r*-plasma. [19c]

Table 3

Inhibitory potencies (IC$_{50}$) on human NAAA of analogues of compound **11h**[a]

Compounds	Structure	h–NAAA IC$_{50}$ (μM) ± S.E.M
12h		74.52 ± 9.08
21h		Not active[b]
22h		Not active[b]
23h		Not active[b]
24h		Not active[b]
27h		Not active[b]
28h		Not active[b]
32		Not active[b]

[a] IC$_{50}$ values are reported as mean values of three or more determinations.

[b] Not active: < 10% inhibition @ 50 μM.

Table 4

Inhibitory potencies (IC$_{50}$) on human NAAA of compounds **11i–q**, **33** and **34**[a]

Compounds	Structure	h–NAAA IC$_{50}$ (µM) ± S.E.M
11i		3.09 ± 0.50
11j		3.90 ± 0.86
11k		13.85 ± 3.41
11l		Not active[b]
11m		0.22 ± 0.03
11n		0.76 ± 0.26
11o		0.24 ± 0.03
11p		0.10 ± 0.02
11q		0.28 ± 0.07
33		5.76 ± 0.90
34		0.24 ± 0.02

[a] IC$_{50}$ values are reported as mean values of three or more determinations.

[b] Not active: < 10% inhibition @ 50 µM.

Table 5

Inhibitory potencies (IC$_{50}$) on human NAAA[a], human AC[a] and % inhibitory activity (% inhib) on human FAAH of compounds **11h, 12h** and **11p**

Compounds	*h*–NAAA IC$_{50}$ (μM) ± SD	*h*–AC IC$_{50}$ (μM) ± SD	*h*–FAAH (% Inhib)[b]
11h	0.13 ± 0.03	2.53 ± 0.06	n.a.
12h	45.54 ± 19.94	27.81 ± 5.38	n.a.
11p	0.056 ± 0.010	0.33 ± 0.10	n.a.

[a] IC$_{50}$ values are measured by LC/MS method and reported as mean values of three or more determinations.

[b] Not active: < 10% inhibition @ 100 μM

Table 6

Plasma pharmacokinetic parameters of compound **11h** after a single intravenous (3.0 mg kg^{-1}) or oral administration (10 mg kg^{-1}) in rats

Parameters	3.0 mg kg^{-1} (IV)[a]	10mg kg^{-1} (PO)[a]
Cmax (ng mL^{-1})	397	570
Tmax (h)	0.08	0.25
AUC (ng h mL^{-1})	111	247
Cl (mL min^{-1} kg^{-1})	702	
F (%)		67

C$_{max}$ = Maximum observed concentration; AUC = Cumulative area under curve for experimental time points (0–24 h); Cl = Systemic clearance based on observed data points (0–24 h); *F* = Bioavailability.

[a] Compound was dosed in 10% PEG400/10% Tween 80/80% Saline solution; three animals per dose were treated.